Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2023 Earnings Call Transcript

Jennifer Chien: Yes. So, as you outlined, I would say that for the most part, just in terms of the three-off period, the payers are following our guidance or label. And so, it’s a bit early just in terms of really reaching that point of time within our launch. With that said, we feel very good just in terms of the positive feedback and the compliance and persistence on therapy to date, which speaks to the benefits. And I think that in general, it will be interesting just in terms of what “clinical benefit is outlined.” I think for the most part, like just want to be reassured that these patients are actually receiving clinical benefit while being on therapy and that’s something that, once again, our patients continue to monitor baseline themselves versus on therapy. So that can also be translated to the physician who could translate that, as well as to the payer.

David Meeker: And just to remind you, Jeff, the label as Jennifer referenced is – it’s 12 months for BBS when the label suggests you should reevaluate. Payers, of course, can choose to do so earlier, but in terms of people tend to be sticking to the label more or less than a year out for months.

Jeff Hung: Great. Great. Thank you.

Operator: Alright. Thank you. We did not have any other questions, so I would now like to turn the conference back to David Meeker for closing remarks.

David Meeker: Great. Well, thank you everyone again for tuning in this morning, and we very much look forward to the next quarter update will disconnect.

Operator: Thank you. So, this concludes today’s conference call. Thank you for participating. You may now disconnect.